Motavizumab

National Cancer Institute

Source

National Cancer Institute. Motavizumab. NCI Thesaurus. Code C88584.

A humanized monoclonal antibody directed against the respiratory syncytial virus (RSV) fusion glycoprotein (F-protein), with activity against RSV. Motavizumab targets and binds to the RSV F-protein, which prevents F-protein-mediated RSV fusion with human host cells. This protects against RSV infection. RSV F-protein mediates RSV attachment and fusion to host cells.